This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2015 Jan;16(1):2-3.

doi: 10.1016/S1470-2045(14)71188-X. Epub 2014 Dec 16.

CDK4/6 inhibitors in luminal breast cancer

Michael Gnant¹, Guenther G Steger², Rupert Bartsch²

Affiliations

Affiliations

¹ Departments of Surgery, Breast Health Center, Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, Austria. Electronic address: michael.gnant@meduniwien.ac.at.
² Internal Medicine I, Breast Health Center, Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, Austria.

PMID: 25524801
DOI: 10.1016/S1470-2045(14)71188-X

Comment

CDK4/6 inhibitors in luminal breast cancer

Michael Gnant et al. Lancet Oncol. 2015 Jan.

. 2015 Jan;16(1):2-3.

doi: 10.1016/S1470-2045(14)71188-X. Epub 2014 Dec 16.

Authors

Michael Gnant¹, Guenther G Steger², Rupert Bartsch²

Affiliations

¹ Departments of Surgery, Breast Health Center, Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, Austria. Electronic address: michael.gnant@meduniwien.ac.at.
² Internal Medicine I, Breast Health Center, Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, Austria.

PMID: 25524801
DOI: 10.1016/S1470-2045(14)71188-X

No abstract available

PubMed Disclaimer

Comment on

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ. Finn RS, et al. Lancet Oncol. 2015 Jan;16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3. Epub 2014 Dec 16. Lancet Oncol. 2015. PMID: 25524798 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal